Medicine guide

Zyclara

  • Prescription status not stated
  • Skin
Active substance
Imiquimod
Used in
Skin
Made by
Viatris Healthcare Limited

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

  • Zyclara is indicated for the topical treatment of clinically typical, non-hyperkeratotic, non-hypertrophic, visible or palpable actinic keratosis of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.

From the official label · 2026-09-30 · European Medicines Agency

How it works

From the US prescribing label for the same active substance (Imiquimod). It describes the substance, not this exact product.

The mechanism of action of imiquimod cream in treating AK and EGW lesions is unknown.

Peak level after9 h
Half-life17 h
Mostly cleared after≈ 4 daysfive half-lives — our arithmetic
PeakHalf gone4 days0
The shape is a standard model drawn from the two times above, not a measurement. How fast a medicine acts and wears off also depends on the dose, the form and the person.

Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-01-21

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

United StatesNo exact match for this strength and form

SpainNo exact match for this strength and form

FranceNo exact match for this strength and form

CanadaNo exact match for this strength and form

NetherlandsNo exact match for this strength and form

SwitzerlandNo exact match for this strength and form

Details

Made byViatris Healthcare Limited
Active substanceImiquimod
Used inSkin
ClassificationD06BB10 · Skin
Authorised on2012-08-23
Last updated by the regulator2025-07-22
EMA product numberEMEA/H/C/002387

Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician

Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.